Publication | Closed Access
Extending the CONSORT Statement to Randomized Trials of Nonpharmacologic Treatment: Explanation and Elaboration
2.2K
Citations
90
References
2008
Year
Non-pharmacological InterventionMeta-analysisHealth PolicyClinical Trial ManagementNonpharmacologic TreatmentPatient SafetyClinical TrialsConsort StatementRandomized TrialsTreatment EffectRandomized Controlled TrialAdequate ReportingDrug TrialFlow DiagramMedicineClinical Trial EvaluationClinical Trial DesignHealth Sciences
Accurate appraisal of randomized trials requires thorough reporting, yet existing CONSORT guidelines inadequately cover nonpharmacologic interventions, and evidence shows persistent reporting deficiencies in this area. The CONSORT group created an extension to address these gaps in reporting for nonpharmacologic treatment trials. A 2006 consensus meeting of 33 experts expanded 11 CONSORT items, added one new item, and produced a modified flow diagram for nonpharmacologic trials. The extension, together with the main CONSORT statement and other extensions, is expected to enhance reporting quality of nonpharmacologic RCTs.
Adequate reporting of randomized, controlled trials (RCTs) is necessary to allow accurate critical appraisal of the validity and applicability of the results. The CONSORT (Consolidated Standards of Reporting Trials) Statement, a 22-item checklist and flow diagram, is intended to address this problem by improving the reporting of RCTs. However, some specific issues that apply to trials of nonpharmacologic treatments (for example, surgery, technical interventions, devices, rehabilitation, psychotherapy, and behavioral intervention) are not specifically addressed in the CONSORT Statement. Furthermore, considerable evidence suggests that the reporting of nonpharmacologic trials still needs improvement. Therefore, the CONSORT group developed an extension of the CONSORT Statement for trials assessing nonpharmacologic treatments. A consensus meeting of 33 experts was organized in Paris, France, in February 2006, to develop an extension of the CONSORT Statement for trials of nonpharmacologic treatments. The participants extended 11 items from the CONSORT Statement, added 1 item, and developed a modified flow diagram. To allow adequate understanding and implementation of the CONSORT extension, the CONSORT group developed this elaboration and explanation document from a review of the literature to provide examples of adequate reporting. This extension, in conjunction with the main CONSORT Statement and other CONSORT extensions, should help to improve the reporting of RCTs performed in this field.
| Year | Citations | |
|---|---|---|
Page 1
Page 1